Filing Flows › BioXcel Therapeutics (BTAIQ) › Q1 2026 › vs Q1 2025
BioXcel Therapeutics (BTAIQ) Q1 2026 vs Q1 2025 (year over year)
BioXcel Therapeutics's revenue rose $38K (+23%) from $168K in Q1 2025 to $206K in Q1 2026.
BioXcel Therapeutics, Q1 2026: revenue $206K (+23% year over year), net loss $12.7M, operating cash flow −$11.8M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $206K | $168K | $38K | +23% |
| Net loss | $12.7M | $7.3M | $5.4M | +75% |
| Costs & expenses | $12.9M | $10.3M | $2.6M | +26% |
| Operating costs | $10.4M | $10.3M | $162K | +2% |
| Interest & other, net | $2.5M | −$2.8M | $5.3M | — |
| Cost of revenue | $283K | $14K | $269K | 20× |
| Research & development | $3.0M | $4.6M | −$1.6M | -35% |
| SG&A | $7.2M | $5.7M | $1.5M | +26% |
| Operating cash sources | $12.7M | $7.3M | $5.4M | +75% |
| Depreciation | $58K | $76K | −$18K | -24% |
| Share-based compensation | $435K | $180K | $255K | +142% |
| Working capital & other | $389K | −$5.0M | $5.4M | — |
| Cash used in operations | $11.8M | $12.0M | −$234K | -2% |
| Net loss absorbed | $12.7M | $7.3M | $5.4M | +75% |
Questions
How much did BioXcel Therapeutics's revenue grow year over year in Q1 2026?
BioXcel Therapeutics's revenue rose $38K (+23%) from $168K in Q1 2025 to $206K in Q1 2026.